Evaro Secures $25M Series A Funding Led by AlbionVC

Why It Matters

By embedding regulated NHS services into everyday consumer platforms, Evaro unlocks scalable health access while easing pressure on the UK’s overstretched primary‑care system.

Key Takeaways

• $25M Series A led by AlbionVC
• Platform integrates NHS services into consumer apps
• Partnerships include Clue and Lovehoney
• Integration possible within two weeks
• Targeting 10M patients by 2029

Pulse Analysis

The UK’s primary‑care bottleneck has become a headline issue, with more than 20 million people waiting a month for a GP appointment in 2024. Against this backdrop, Evaro’s digital health‑as‑a‑service platform offers a pragmatic alternative: it delivers fully regulated NHS‑licensed consultations, prescriptions and after‑care through any consumer‑facing app. By leveraging asynchronous consultations and remote diagnostics, the service can be rolled out in days, giving users the convenience of online banking while freeing clinician capacity for complex cases.

Evaro’s competitive edge lies in its seven‑year‑old regulatory stack, including CQC and GPhC licences and direct GP‑record access. The API‑first architecture lets brands such as period‑tracking app Clue and sexual‑wellness retailer Lovehoney embed prescription pathways with as little as two weeks of integration work. For partners, this creates a new, high‑margin revenue stream without building clinical infrastructure, while patients benefit from a seamless, Trustpilot‑rated experience. Investors see the model as the health analogue of embedded finance, unlocking latent demand across consumer, provider and employer segments.

The fresh $25 million Series A will fund expansion into women’s health, men’s health and longevity medicine, as well as advanced diagnostics and after‑care services. Evaro aims to serve 10 million patients within three years, positioning itself as the backbone for a new category of embedded healthcare in the UK. If successful, the approach could relieve chronic NHS pressure, accelerate digital transformation for brands, and set a template for other markets. Stakeholders—from venture capitalists to corporate strategists—are watching closely as the company scales its regulatory‑compliant infrastructure.

Deal Summary

Evaro, an NHS‑licensed digital health platform, raised $25 million in a Series A round led by AlbionVC with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC and BBI. The funding will accelerate its healthcare‑as‑a‑service model across consumer brands, healthcare organisations and employers.